MedTrace Logo

Growth of Infants Fed an Extensively Hydrolyzed Infant Formula

NCT01210391 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 282

Last updated 2014-06-26

No results posted yet for this study

Summary

The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.

Conditions

  • Growth

Interventions

OTHER

Extensively hydrolyzed whey infant formula

New hydrolyzed infant formula.

OTHER

Extensively hydrolyzed casein infant formula

Commercially available infant formula.

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Ricardo Sorensen, MD · Louisiana State University Health Sciences Center in New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
11 Days
Max Age
4 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01210391 on ClinicalTrials.gov